Results 21 to 30 of about 10,275 (197)

Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression in endometrial carcinosarcoma [PDF]

Gynecologic Oncology Reports
Objective: To characterize the immunohistochemical expression of human epidermal growth factor receptor-2 (HER2), nectin-4, and trophoblast cell surface antigen-2 (TROP2) in endometrial carcinosarcoma (ECS), with particular attention to compartment ...
Shih-Yao Lin, Chung-Ting Chang, Ren-Chin Wu, Chiung-Ru Lai, Yi-Jen Chen   +4 more
doaj   +2 more sources

A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE [PDF]

Cell Death and Disease
Research and development on Nectin-4 antibody-drug conjugates (ADC) have been greatly accelerated since the approval of enfortumab vedotin to treat uroepithelial cancer.
Yichen Wang, Yanyang Nan, Chunguang Ma, Xiaolin Lu, Qian Wang, Xiting Huang, Wenjing Xue, Jiajun Fan, Dianwen Ju, Dingwei Ye, Xuyao Zhang   +10 more
doaj   +2 more sources

Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs [PDF]

BMC Cancer
Upper tract urothelial carcinoma (UTUC) and urinary bladder cancer (UBC), though histologically similar, differ molecularly, prompting interest in their biomarker profiles for targeted therapies like antibody-drug conjugates (ADCs) enfortumab vedotin ...
Mohammed Rafea Kanaan, Jessica Schmitz, Jan Hinrich Braesen, Markus Antonius Kuczyk, Hossein Tezval   +4 more
doaj   +2 more sources

Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin‐4 Loss [PDF]

IJU Case Reports
Introduction Enfortumab vedotin is a standard therapy for advanced urothelial carcinoma, but its efficacy may be limited by acquired resistance and spatial heterogeneity of Nectin‐4 expression.
Takahito Wakamiya, Yuya Iwahashi, Hiroki Kawabata, Satoshi Muraoka, Shimpei Yamashita, Fumiyoshi Kojima, Yasuo Kohjimoto   +6 more
doaj   +2 more sources

Biodistribution, dosimetry, and preliminary imaging of the novel Nectin-4–targeting PET tracer [⁶⁸Ga]Ga-FZ-NR-1 in humans [PDF]

EJNMMI Research
Background Nectin-4 is a promising theranostic target for cancers treatment due to its high abundance/expression in different cancer entities such as bladder cancer, breast cancer, and pancreatic cancer This study evaluated the biodistribution and ...
Xiaoqiang Shi, Hongxing Yang, Ming Qi, Wen Chen, Haoyao Guo, Meng Xiao, Chunjuan Jiang, Ni Zhang, Zhihao Chen, Xiaoping Xu, Shaoli Song, Jianping Zhang   +11 more
doaj   +2 more sources

Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers [PDF]

Journal for ImmunoTherapy of Cancer
Background T-cell costimulation is crucial for an effective and sustained antitumor immune response, and inadequate expression of costimulatory ligands within tumors can impair T-cell function.
Manpreet Kaur, Starlynn C Clarke, Katherine E Harris, Nathan D Trinklein, Elaine C Chen, Katja Rüger, Udaya S Rangaswamy, Laura M Davison, Sebastian Moreno Arteaga, Imani Smith, Ruth Chu, Soumili Chattopadhyay, Mathias Rickert, Shelley Force Aldred   +13 more
doaj   +2 more sources

A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer [PDF]

Journal of Nanobiotechnology
Background Gastric cancer represents a highly lethal malignancy with an elevated mortality rate among cancer patients, coupled with a suboptimal postoperative survival prognosis. Nectin-4, an overexpressed oncological target for various cancers, has been
Yue Wu, Min Zhu, Baihe Sun, Yongting Chen, Yuping Huang, Junwei Gai, Guanghui Li, Yanfei Li, Yakun Wan, Linlin Ma   +9 more
doaj   +2 more sources

Expression of nectin-4 in prostate cancer. [PDF]

North Clin Istanb, 2023
Nectin-4 is a transmembrane protein belonging to the nectin family of immunoglobulin-like molecules which is found in the placenta and trachea under physiological conditions and its expression has been shown in many cancer types. We aimed to investigate for the 1st time nectin-4 expression in human prostate cancer tissues.We retrospectively analyzed ...
Ordu M, Karaaslan M, Sirin ME, Yilmaz M.
europepmc   +4 more sources

TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma. [PDF]

Pathologica
Introduction. The surface protein TROP-2/TACSTD2 and the cell adhesion protein NECTIN-4/NECTIN4 are responsible for the efficacy of anticancer therapies based on antibody- drug conjugates (ADC) targeting intracellular microtubules.
Brunelli M, Gobbo S, Malpeli G, Sirgiovanni G, Caserta C, Munari E, Francesconi S, Caliò A, Martignoni G, Cimadamore A, Veccia A, Antonelli A, Tucci M, Pierconti F, Hattab IM, Eccher A, Ascani S, Milella M, Buffoni L, Cheng L, Bracarda S.   +20 more
europepmc   +3 more sources

Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies [PDF]

, 2012
Lentiviral vectors (LVs) are potent gene transfer vehicles frequently applied in research and recently also in clinical trials. Retargeting LV entry to cell types of interest is a key issue to improve gene transfer safety and efficacy.
Abel, Tobias, Brynza, Julia, Buchholz, Christian J., Kneissl, Sabrina, Rasbach, Anke, Schneider-Schaulies, Jürgen   +5 more
core   +15 more sources